Date:12/11/2008

EQUITY CURRENT LIABILITIES: Current portion of long-term debt $2,651,592 $- Current portion of capital lease obligation 41,641 159,440 Accounts payable 2,466,052 3,281,600 Accrued expenses 6,182,417 5,513,407 Deferred rent 124,463 124,462 Deferred revenue 1,857,136 1,857,136 Total current liabilities 13,323,301 10,936,045 DEFERRED RENT 79,793 204,256 NON CURRENT PORTION OF CAPITAL LEASE OBLIGATION - 41,641 DEFERRED REVENUE 3,868,965 5,726,131 LONG-TERM DEBT, net 16,522,665 - Total liabilities 33,794,724 16,908,073 COMMITMENTS & CONTINGENCIES STOCKHOLDERS' EQUITY Common Stock, $0.001 par value, 100,000,000 shares authorized, 23,340,498 and 21,232,991 shares issued and outstanding at September 30, 2008, and September 30, 2007, respectively 23,340 21,233 Warrants to purchase 116,183 shares of common stock for $12.05 per share, with 66,390 exercisable starting September 30, 2007, and 49,793 shares exercisable starting March 28, 2008 1,140,114 526,720 Additional paid-in capital 145,818,439 115,518,201 Accumulated other comprehensive (loss) income
'/>"/>

SOURCE Pharmasset, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
3. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
4. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
5. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
6. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
7. Pharmasset Receives Notice of Allowance
8. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Pharmasset Reports First Fiscal Quarter 2008 Financial Results